M&A Deal Summary

MPE Partners and Montreux Equity Partners Acquires OREXIGEN Therapeutics

On November 22, 2006, private equity firm MPE Partners and growth capital firm Montreux Equity Partners acquired life science company OREXIGEN Therapeutics, Inc. for 30M USD

Acquisition Highlights
  • This is MPE Partners’ 4th and Montreux Equity Partners’ 4th transaction in the Life Science sector.
  • This is MPE Partners’ 1st and Montreux Equity Partners’ 1st largest (disclosed) transaction.
  • This is MPE Partners’ 36th and Montreux Equity Partners’ 11th transaction in the United States.
  • This is MPE Partners’ 16th and Montreux Equity Partners’ 11th transaction in California.
Investment Fate
  • OREXIGEN Therapeutics was sold to a strategic buyer in 2018 for 75M USD.

M&A Deal Summary

Date 2006-11-22
Target OREXIGEN Therapeutics, Inc.
Sector Life Science
Buyer(s) MPE Partners
Montreux Equity Partners
Deal Type Buyout (LBO, MBO, MBI)
Deal Value 30M USD

Target

OREXIGEN Therapeutics, Inc.

La Jolla, California, United States
website
Orexigen Therapeutics, Inc. is a bio-pharmaceutical company focuses on the treatment of obesity. The Company's lead product candidate is Contrave, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA.

Search 163,065 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 2

Buyer

MPE Partners

Cleveland, Ohio, United States

Investor Investor Investor Investor Investor

website


Category Private Equity Firm
Founded 1968
PE ASSETS 3.0B USD
SizeMega
Type Sector Agnostic
DESCRIPTION

Morgenthaler is a Midwest based investment firm focused on venture capital and private equity investments. Morgenthaler's private equity group invests in profitable, lower middle-market businesses in the form of management led buyouts, leveraged build-ups, or recapitalization. The Group looks for stand-alone companies operating in the 'high-value' manufacturing or business services sectors. Morgenthaler seeks transactions valued from $25 to $250 million and EBITDA of excess $5 million. The Group will consider opportunities throughout North America, Europe, and Asia. Morgenthaler has offices in Cleveland, Ohio and Boston, Massachusetts.


DEAL STATS #
Overall 38 of 77
Sector (Life Science) 4 of 13
Type (Buyout (LBO, MBO, MBI)) 4 of 7
State (California) 16 of 25
Country (United States) 36 of 74
Year (2006) 6 of 6
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2006-11-10 Solta Medical, Inc.

Hayward, California, United States

Solta Medical, Inc. is a designer, developer, manufacturer and marketer of medical devices for the non-invasive treatment of wrinkles.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2007-02-13 Trellis Bioscience, Inc.

South San Francisco, California, United States

Trellis Bioscience, Inc. is a privately held biotechnology company that developed a breakthrough technology platform for discovery and selection of very rare cells that produce ideal proteins such as antibodies, selected for specificity, selectivity, affinity, secretion rate and other desired characteristics.

Buy -
Buyer

Montreux Equity Partners

Investor Investor Investor Investor Investor

website


Category Growth Capital Firm
Founded 1993
SizeSmall
Type Sector Agnostic
DESCRIPTION

Montreux Equity Partners is a growth investment firm focused on investing in commercial stage companies with category leading products, technologies, and services. Montreux Equity Partners looks to invest $10 to $20 million in fast growing companies with $5 to $50 million in revenue. Montreux Equity Partners was formed in 1993 and is headquartered in San Francisco, California.


DEAL STATS #
Overall 11 of 25
Sector (Life Science) 4 of 8
Type (Buyout (LBO, MBO, MBI)) 1 of 3
State (California) 11 of 19
Country (United States) 11 of 23
Year (2006) 2 of 2
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2006-01-01 Avantis Medical Systems, Inc.

San Jose, California, United States

Avantis Medical Systems, Inc. develops and manufactures catheter-based endoscopic devices. Its initial focus is on devices for use in both detecting and treating cancers of the gastrointestinal (GI) tract. Avantis Medical Systems was founded in 2004 and is based in San Jose, California.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2007-01-01 Cerexa, Inc.

Oakland, California, United States

Cerexa, Inc. was a privately held specialty pharmaceutical company, created as a spin-out from the sale of Peninsula Pharmaceuticals to Johnson & Johnson, focused on developing and commercializing novel anti-infective therapies for the treatment of life-threatening infections.

Sell $480M